Dr. Lynn Hillyer:

The panel of substances, by which I mean both the range of substances we test for and the depth or sensitivity of that testing, is always moving forwards. One of the reasons we set our standards so high in terms of our contracted laboratory is to make sure that laboratory stays ahead of the curve. The most tangible example I can give the Senator at the moment relates to the detection of gene doping. Since we last met here, the detection of gene doping has become a reality. Tests have been developed and research has been done. LGC is at the forefront of that research and is implementing it. Exactly as the Senator has said, we have to stay ahead of that curve. There are new substances coming in. Some are rumours and some are real but we have to follow up on all of them. That is why that laboratory, being one of only six IFHA-certified laboratories in the world, is so important. It has its area of expertise and talks to its colleagues in the other five laboratories. Those laboratories share their methods and make sure they are all working together to detect these doping agents.